What factors influence Omega Therapeutics, Inc. stock price forecasts?

Our analysis considers financial metrics, sector trends, market sentiment, technical indicators, and macroeconomic factors.

Eintragen

Herzlich willkommen!

Mein Konto
Abmeldung

Omega Therapeutics, Inc. (OMGA) Aktienprognose 2025 - KI-Preisvorhersage & Analyse

Omega Therapeutics, Inc. (OMGA) AI-Aktienkursprognose & Investitionsanalyse

Letzte Analyse Datum: März 07, 2025

Loading Omega Therapeutics, Inc. interaktives Kursdiagramm und technische Analyse...

Omega Therapeutics, Inc. (OMGA) - Umfassende Aktienanalyse & Investment Research

Deep dive into Omega Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Omega Therapeutics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

Für Omega Therapeutics, Inc.: Omega Therapeutics, Inc. operates in the Life Sciences sector, making it an emerging small-cap investment.

Omega Therapeutics, Inc. (Börsenkürzel: OMGA) ist ein führendes Unternehmen in der Life Sciences Branche die speziell in der Branche Biological Products, (No Diagnostic Substances) tätig sind.

Die Organisation beschäftigt weltweit etwa 137 Fachkräfte .

Das Unternehmen hat sich etabliert als eine aufstrebende Investitionsmöglichkeit mit erheblichem Wachstumspotenzial.

Understanding Financial Performance

Was diese Metriken bedeuten: Key financial indicators showing Omega Therapeutics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

Wie man sie liest: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

Für Omega Therapeutics, Inc.: With $7M in annual revenue and -742,2% net margin, the company demonstrates developing profitability.

Jährliche Einnahmen: $7 Millionen Erzielung einer -742,2% Nettogewinnspanne .

Marktkapitalisierung: $9 Millionen - Einstufung als Small-Cap-Anlage mit hohem Wachstumspotenzial.

Eigenkapitalrendite (ROE): -144,9% - Unterdurchschnittlich Effizienz der Aktionärsrendite, was darauf hindeutet Bereiche für operative Verbesserungen.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Omega Therapeutics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

Für Omega Therapeutics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Premium-KI-Vorhersagen freischalten um auf unsere fortschrittlichen Machine-Learning-Prognosen für die Omega Therapeutics, Inc.-Aktie zuzugreifen, einschließlich 7-Tage-, 30-Tage- und 90-Tage-Kurszielen mit Konfidenzintervallen und Risikoeinschätzungen.

Understanding Market Position

What this analysis covers: Omega Therapeutics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

Für Omega Therapeutics, Inc.: Market positioning analysis based on available financial and operational metrics.

Omega Therapeutics, Inc. konkurriert strategisch auf dem hochdynamischen Biological Products, (No Diagnostic Substances) marktplatz, eine aufstrebende Small-Cap-Investition mit erheblichem Wachstumspotenzial und der Fähigkeit, den Markt zu verändern .

Das Unternehmen weist eine gesunde 100,0% Bruttomarge auf, was auf eine starke Preissetzungsmacht und betriebliche Effizienz hindeutet.

Omega Therapeutics, Inc. (OMGA) Fundamentalanalyse & Insiderhandelsdaten (Vierteljährliche Finanzberichte)

Umfassende vierteljährliche Finanzdaten, Gewinntrends, Insidertransaktionen und institutionelle Beteiligungen für Omega Therapeutics, Inc. Aktienanalyse.

Loading Omega Therapeutics, Inc. umfassende Fundamentalanalyse und Insiderhandelsdaten...

Tiefe Einblicke in die finanzielle Gesundheit, die Bewertungskennzahlen und die betriebliche Effizienz von Omega Therapeutics, Inc., um fundierte Investitionsentscheidungen zu treffen.

Bewertungsmetriken verstehen

Was diese Metriken bedeuten: Mit Hilfe von Bewertungskennzahlen lässt sich feststellen, ob eine Omega Therapeutics, Inc.-Aktie im Vergleich zu ihren Erträgen, Vermögenswerten und ihrer Marktposition einen fairen Preis hat.

Wie man sie liest: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

Für Omega Therapeutics, Inc.: Bei einem Kurs-Gewinn-Verhältnis von -0,68 ist der Markt hält die Aktie für potenziell unterbewertet.

P/E Ratio -0,68x

P/B Ratio 0,77x

Market Cap $9M

EPS $-1,42

Buchwert/Aktie $0,21

Umsatz/Aktie $-0,43

Rentabilitätsmetriken verstehen

Was diese Metriken bedeuten: Diese Kennzahlen messen, wie effizient Omega Therapeutics, Inc. Einnahmen in Gewinn umwandelt und Renditen für die Aktionäre erwirtschaftet.

Wie man sie liest: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

Für Omega Therapeutics, Inc.: Eine Eigenkapitalrendite von -144,9% zeigt Raum für Verbesserungen bei Wertschöpfung für die Aktionäre.

ROE -144,9%

ROA -41,5%

ROIC -106,3%

Gross Margin 100,0%

Operating Margin -934,2%

Net Margin -742,2%

Finanzielle Gesundheitsmetriken verstehen

Was diese Metriken bedeuten: Diese Kennzahlen bewerten die Fähigkeit von Omega Therapeutics, Inc., kurzfristigen Verpflichtungen nachzukommen und den Schuldenstand effektiv zu verwalten.

Wie man sie liest: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

Für Omega Therapeutics, Inc.: Ein aktuelles Verhältnis von 15,23 deutet auf eine hohe Liquidität hin.

Current Ratio 15,23x

Quick Ratio 14,93x

D/E Ratio 0,12x

Financial Leverage 1,20x

Interest Coverage -86,9x

Cashflow-Metriken verstehen

Was diese Metriken bedeuten: Die Cashflow-Kennzahlen geben Aufschluss über die Fähigkeit von Omega Therapeutics, Inc., Mittel aus dem operativen Geschäft zu generieren und Wachstumsinitiativen zu finanzieren.

Wie man sie liest: Ein positiver operativer Cashflow ist entscheidend. Der freie Cashflow zeigt, wie viel Geld für Dividenden, Rückkäufe oder Investitionen zur Verfügung steht.

Für Omega Therapeutics, Inc.: Freier Cashflow von $-72M weist auf Bargeldprobleme hin, die Aufmerksamkeit erfordern.

Operating Cash Flow $-70M

Free Cash Flow $-72M

Capital Spending $-2M

CapEx/Sales 381,3%

Metriken für die betriebliche Effizienz verstehen

Was diese Metriken bedeuten: Diese Kennzahlen messen, wie effektiv Omega Therapeutics, Inc. sein Vermögen einsetzt und das Betriebskapital verwaltet.

Wie man sie liest: Höhere Umschlagshäufigkeiten deuten auf eine effiziente Nutzung der Vermögenswerte hin. Kürzere Inkassofristen zeigen ein effizientes Kreditmanagement.

Für Omega Therapeutics, Inc.:

Receivables Turnover 1,3x

Fixed Assets Turnover 0,1x

Offene Verkaufstage 285 Tage

Verstehen von Jahresabschlussdaten

Was diese Metriken bedeuten: Schlüsselzahlen aus der Gewinn- und Verlustrechnung und der Bilanz von Omega Therapeutics, Inc., die die absolute finanzielle Leistung zeigen.

Wie man sie liest: Die Einnahmen zeigen die Größe des Unternehmens, während die Gewinnspannen die Rentabilität anzeigen. Die Bilanzposten geben Aufschluss über die Finanzstruktur.

Für Omega Therapeutics, Inc.: Mit einem Jahresumsatz von $7M, Omega Therapeutics, Inc. ein kleineres, aber potenziell wachstumsstarkes Unternehmen darstellt.

Gewinn- und Verlustrechnung ($ Millionen)

Gesamteinnahmen $7M

Betriebseinkommen $-74M

Reingewinn $-73M

F&E-Ausgaben $57M

Kosten der verkauften Waren $-28M

Highlights der Bilanz (% Of Assets)

Total Current Assets 95%

Cash & Short-term Investments 92%

Total Liabilities 17%

Short-term Debt 2%

Accounts Receivable 1%

Informationen zu Dividende und Aktionären

Shares Outstanding 55M

Wachstumsmetriken (YoY)

EPS Growth -149,5%

Neueste Omega Therapeutics, Inc. Aktiennachrichten und Marktanalysen

Aktuelle Nachrichten, Analystenberichte und Marktaktualisierungen, die den Aktienkurs und die Investitionsaussichten von Omega Therapeutics, Inc. (OMGA) betreffen.

Omega Therapeutics, Inc. (OMGA) Surges 37.2%: Is This an Indication of Further Gains?

2y ago, Quelle: Yahoo Finance

Omega Therapeutics, Inc. (OMGA) shares ended the last trading session 37.2% higher at $6.60. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates

2y ago, Quelle: Yahoo Finance

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.54 per share a year ago. These ...

Omega Therapeutics, Inc. (OMGA) Upgraded to Buy: What Does It Mean for the Stock?

3y ago, Quelle: Nasdaq

Investors might want to bet on Omega Therapeutics, Inc. (OMGA), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung Cancer

2y ago, Quelle: Seeking Alpha

OTX-2101 is the Second Development Candidate Arising from the Company's Pioneering OMEGA Epigenomic Programming™ Platform CAMBRIDGE, Mass., Oct. 12, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (OMGA ...

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers

1y ago, Quelle: Business Insider

Programmable epigenomic mRNA candidates enabled durable and robust upregulation of gene expression across a diverse set of gene types and regulatory mechanisms Additional OMEGA platform capabilities ...

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

1y ago, Quelle: Seeking Alpha

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial ...

10mon ago, Quelle: The Globe and Mail

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic ...

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors

1y ago, Quelle: Business Insider

CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable ...

Omega Therapeutics Inc

1y ago, Quelle: ig.com

If your aggregate position is larger than Tier 1, your margin requirement will not be reduced by non-guaranteed stops. Please note: we have tried to ensure that the information here is as accurate as ...

Omega Therapeutics, Inc. (OMGA) Surges 19.6%: Is This an Indication of Further Gains?

2y ago, Quelle: Nasdaq

Omega Therapeutics, Inc. (OMGA) shares rallied 19.6% in the last trading session to close at $7.19. This move can be attributable to notable volume with a higher number of shares being traded than in ...

Omega Therapeutics, Inc. Wettbewerber und Peer-Analyse - Life Sciences Sektor

Vergleichende Analyse von Omega Therapeutics, Inc. mit Branchenkollegen und Wettbewerbern im Life Sciences-Sektor, mit KI-gestützten Prognosen und wichtigen Finanzkennzahlen.

Unternehmen	Ticker-Symbol	90-Tage-Prognose für AI	Marktkapitalisierung (USD Mio.)	Kurs-Gewinn-Verhältnis	P/B-Verhältnis
Acumen Pharmaceuticals, Inc.	ABOS	Unlock Forecast - 30 Days FREE Trial	$85M	-1,9x	0,7x
Abpro Holdings, Inc.	ABP	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Abpro Holdings, Inc.	ABPWW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Arcellx, Inc.	ACLX	Unlock Forecast - 30 Days FREE Trial	$3725M	-74,1x	8,9x
Alpha Cognition Inc.	ACOG	Unlock Forecast - 30 Days FREE Trial	$143M	x	4,5x
Adaptimmune Therapeutics PLC	ADAP	Unlock Forecast - 30 Days FREE Trial	$65M	-13,2x	-11,8x
ADMA BIOLOGICS, INC.	ADMA	Unlock Forecast - 30 Days FREE Trial	$3873M	18,5x	9,7x
Adaptive Biotechnologies Corp	ADPT	Unlock Forecast - 30 Days FREE Trial	$2067M	-4,6x	11,5x
Adverum Biotechnologies, Inc.	ADVM	Unlock Forecast - 30 Days FREE Trial	$58M	-1,8x	2,2x
AGENUS INC	AGEN	Unlock Forecast - 30 Days FREE Trial	$130M	-0,5x	-0,5x
AIM ImmunoTech Inc.	AIM	Unlock Forecast - 30 Days FREE Trial	$2M	-0,5x	-183,3x
AIM ImmunoTech Inc.	AIMI	Unlock Forecast - 30 Days FREE Trial	$2M	x	x
Alector, Inc.	ALEC	Unlock Forecast - 30 Days FREE Trial	$305M	-1,2x	4,3x
Aligos Therapeutics, Inc.	ALGS	Unlock Forecast - 30 Days FREE Trial	$107M	-19,2x	1,1x
Allogene Therapeutics, Inc.	ALLO	Unlock Forecast - 30 Days FREE Trial	$253M	-1,4x	0,7x
Kalaris Therapeutics, Inc.	ALVR	Unlock Forecast - 30 Days FREE Trial	$49M	-0,5x	0,4x
AMGEN INC	AMGN	Unlock Forecast - 30 Days FREE Trial	$150674M	22,8x	20,3x
Apogee Therapeutics, Inc.	APGE	Unlock Forecast - 30 Days FREE Trial	$2195M	-20,5x	4,3x
Aptose Biosciences Inc.	APTO	Unlock Forecast - 30 Days FREE Trial	$6M	0,0x	-1,3x
Aptose Biosciences Inc.	APTOF	Unlock Forecast - 30 Days FREE Trial	$3M	x	x
Armata Pharmaceuticals, Inc.	ARMP	Unlock Forecast - 30 Days FREE Trial	$103M	-1,0x	-1,6x
Artiva Biotherapeutics, Inc.	ARTV	Unlock Forecast - 30 Days FREE Trial	$88M	x	0,6x
Athira Pharma, Inc.	ATHA	Unlock Forecast - 30 Days FREE Trial	$15M	-0,2x	0,5x
Atara Biotherapeutics, Inc.	ATRA	Unlock Forecast - 30 Days FREE Trial	$149M	25,8x	-1,1x
aTYR PHARMA INC	ATYR	Unlock Forecast - 30 Days FREE Trial	$515M	-3,6x	6,9x
Aura Biosciences, Inc.	AURA	Unlock Forecast - 30 Days FREE Trial	$402M	-4,9x	2,3x
Autolus Therapeutics plc	AUTL	Unlock Forecast - 30 Days FREE Trial	$389M	x	1,1x
ANAVEX LIFE SCIENCES CORP.	AVXL	Unlock Forecast - 30 Days FREE Trial	$758M	-17,3x	8,3x
BioAtla, Inc.	BCAB	Unlock Forecast - 30 Days FREE Trial	$125M	-1,1x	1,0x
BioCardia, Inc.	BCDA	Unlock Forecast - 30 Days FREE Trial	$12M	-0,6x	-7,8x
BRAINSTORM CELL THERAPEUTICS INC.	BCLI	Unlock Forecast - 30 Days FREE Trial	$7M	-4,9x	-0,9x
BIOCRYST PHARMACEUTICALS INC	BCRX	Unlock Forecast - 30 Days FREE Trial	$1802M	-12,1x	-4,0x
Black Diamond Therapeutics, Inc.	BDTX	Unlock Forecast - 30 Days FREE Trial	$171M	11,8x	1,3x
Beam Therapeutics Inc.	BEAM	Unlock Forecast - 30 Days FREE Trial	$2115M	-12,6x	2,0x
BIOGEN INC.	BIIB	Unlock Forecast - 30 Days FREE Trial	$18125M	12,8x	1,5x
Black Hawk Acquisition Corp	BKHA	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Black Hawk Acquisition Corp	BKHAU	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
bluebird bio, Inc.	BLUE	Unlock Forecast - 30 Days FREE Trial	$49M	-0,2x	-0,8x
Cabaletta Bio, Inc.	CABA	Unlock Forecast - 30 Days FREE Trial	$155M	-1,6x	0,9x
Candel Therapeutics, Inc.	CADL	Unlock Forecast - 30 Days FREE Trial	$338M	-4,6x	4,5x
C4 Therapeutics, Inc.	CCCC	Unlock Forecast - 30 Days FREE Trial	$193M	-2,6x	1,1x
Cidara Therapeutics, Inc.	CDTX	Unlock Forecast - 30 Days FREE Trial	$728M	-1,0x	5,1x
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.	CELZ	Unlock Forecast - 30 Days FREE Trial	$9M	-3,4x	1,3x
CERO THERAPEUTICS HOLDINGS, INC.	CERO	Unlock Forecast - 30 Days FREE Trial	$2M	x	-196,2x
CERO THERAPEUTICS HOLDINGS, INC.	CEROW	Unlock Forecast - 30 Days FREE Trial	$2M	x	-0,5x
Cullinan Therapeutics, Inc.	CGEM	Unlock Forecast - 30 Days FREE Trial	$449M	-4,1x	0,8x
COMPUGEN LTD	CGEN	Unlock Forecast - 30 Days FREE Trial	$134M	x	2,7x
CG Oncology, Inc.	CGON	Unlock Forecast - 30 Days FREE Trial	$2529M	x	3,8x
COGNITION THERAPEUTICS INC	CGTX	Unlock Forecast - 30 Days FREE Trial	$170M	-0,5x	24,1x
Pelthos Therapeutics Inc.	CHRO	Unlock Forecast - 30 Days FREE Trial	$8M	x	-2,0x
Coherus Oncology, Inc.	CHRS	Unlock Forecast - 30 Days FREE Trial	$150M	0,8x	1,3x
Calidi Biotherapeutics, Inc.	CLDI	Unlock Forecast - 30 Days FREE Trial	$5M	-0,9x	3,1x
Compass Therapeutics, Inc.	CMPX	Unlock Forecast - 30 Days FREE Trial	$483M	-4,8x	5,2x
Coeptis Therapeutics Holdings, Inc.	COEPW	Unlock Forecast - 30 Days FREE Trial	$M	x	x
Caribou Biosciences, Inc.	CRBU	Unlock Forecast - 30 Days FREE Trial	$174M	-1,5x	1,1x
Cardiff Oncology, Inc.	CRDF	Unlock Forecast - 30 Days FREE Trial	$144M	-4,0x	2,5x
CARGO Therapeutics, Inc.	CRGX	Unlock Forecast - 30 Days FREE Trial	$215M	x	0,9x
CURIS INC	CRIS	Unlock Forecast - 30 Days FREE Trial	$18M	-0,3x	-2,9x
CRISPR Therapeutics AG	CRSP	Unlock Forecast - 30 Days FREE Trial	$4579M	-12,1x	2,7x
CHAMPIONS ONCOLOGY, INC.	CSBR	Unlock Forecast - 30 Days FREE Trial	$111M	-17,8x	20,4x
CEL SCI CORP	CVM	Unlock Forecast - 30 Days FREE Trial	$56M	-0,9x	8,0x
Cyclo Therapeutics, Inc.	CYTH	Unlock Forecast - 30 Days FREE Trial	$26M	-0,6x	-1,9x
Cyclo Therapeutics, Inc.	CYTHW	Unlock Forecast - 30 Days FREE Trial	$7M	x	-0,5x
DBV Technologies S.A.	DBVT	Unlock Forecast - 30 Days FREE Trial	$1479M	-3,3x	514,8x
Ginkgo Bioworks Holdings, Inc.	DNA	Unlock Forecast - 30 Days FREE Trial	$568M	-13,9x	0,3x
Denali Therapeutics Inc.	DNLI	Unlock Forecast - 30 Days FREE Trial	$2111M	-8,7x	1,9x
PRECISION BIOSCIENCES INC	DTIL	Unlock Forecast - 30 Days FREE Trial	$59M	-2,2x	1,7x
DYADIC INTERNATIONAL INC	DYAI	Unlock Forecast - 30 Days FREE Trial	$28M	-7,3x	11,4x
Editas Medicine, Inc.	EDIT	Unlock Forecast - 30 Days FREE Trial	$231M	-0,8x	3,7x
Elevation Oncology, Inc.	ELEV	Unlock Forecast - 30 Days FREE Trial	$22M	-1,0x	0,5x
ELUTIA INC.	ELUT	Unlock Forecast - 30 Days FREE Trial	$84M	-1,4x	-0,1x
enGene Holdings Inc.	ENGN	Unlock Forecast - 30 Days FREE Trial	$276M	3,7x	1,2x
enGene Holdings Inc.	ENGNW	Unlock Forecast - 30 Days FREE Trial	$37M	x	0,1x
Entera Bio Ltd.	ENTX	Unlock Forecast - 30 Days FREE Trial	$94M	8,5x	5,4x
ENZO BIOCHEM INC	ENZ	Unlock Forecast - 30 Days FREE Trial	$25M	-3,0x	0,5x
ENZO BIOCHEM INC	ENZB	Unlock Forecast - 30 Days FREE Trial	$37M	x	0,8x
Estrella Immunopharma, Inc.	ESLA	Unlock Forecast - 30 Days FREE Trial	$39M	-3,1x	-16,9x
Estrella Immunopharma, Inc.	ESLAW	Unlock Forecast - 30 Days FREE Trial	$4M	x	5,3x
EXELIXIS, INC.	EXEL	Unlock Forecast - 30 Days FREE Trial	$10793M	17,9x	5,3x
EXOZYMES INC.	EXOZ	Unlock Forecast - 30 Days FREE Trial	$100M	x	13,9x
FATE THERAPEUTICS INC	FATE	Unlock Forecast - 30 Days FREE Trial	$115M	-1,3x	0,4x
4D Molecular Therapeutics, Inc.	FDMT	Unlock Forecast - 30 Days FREE Trial	$406M	-3,0x	1,0x
FENNEC PHARMACEUTICALS INC.	FENC	Unlock Forecast - 30 Days FREE Trial	$250M	1758,3x	-39,7x
Finch Therapeutics Group, Inc.	FNCH	Unlock Forecast - 30 Days FREE Trial	$20M	-0,1x	1,4x
FutureTech II Acquisition Corp.	FTII	Unlock Forecast - 30 Days FREE Trial	$-26M	x	-0,7x
FutureTech II Acquisition Corp.	FTIIU	Unlock Forecast - 30 Days FREE Trial	$-26M	x	-0,8x
FutureTech II Acquisition Corp.	FTIIW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
GILEAD SCIENCES, INC.	GILD	Unlock Forecast - 30 Days FREE Trial	$144869M	23,0x	7,4x
Monte Rosa Therapeutics, Inc.	GLUE	Unlock Forecast - 30 Days FREE Trial	$398M	16,5x	1,5x
Genenta Science S.p.A.	GNTA	Unlock Forecast - 30 Days FREE Trial	$64M	x	5,1x
Green Planet Bio Engineering Co. Ltd.	GPLB	Unlock Forecast - 30 Days FREE Trial	$M	x	x
HALOZYME THERAPEUTICS, INC.	HALO	Unlock Forecast - 30 Days FREE Trial	$9509M	17,1x	28,6x
HilleVax, Inc.	HLVX	Unlock Forecast - 30 Days FREE Trial	$105M	-0,6x	0,7x
Humacyte, Inc.	HUMA	Unlock Forecast - 30 Days FREE Trial	$224M	-3,3x	55,2x
Humacyte, Inc.	HUMAW	Unlock Forecast - 30 Days FREE Trial	$163M	x	-2,6x
ImmunityBio, Inc.	IBRX	Unlock Forecast - 30 Days FREE Trial	$2427M	-3,6x	-4,1x
Ikena Oncology, Inc.	IKNA	Unlock Forecast - 30 Days FREE Trial	$61M	-1,3x	0,5x
Inhibikase Therapeutics, Inc.	IKT	Unlock Forecast - 30 Days FREE Trial	$150M	-1,0x	1,9x
Immunocore Holdings plc	IMCR	Unlock Forecast - 30 Days FREE Trial	$1831M	x	4,7x
Immunovant, Inc.	IMVT	Unlock Forecast - 30 Days FREE Trial	$2816M	-14,5x	4,6x
IN8BIO, INC.	INAB	Unlock Forecast - 30 Days FREE Trial	$21M	-0,4x	2,4x
Inhibrx Biosciences, Inc.	INBX	Unlock Forecast - 30 Days FREE Trial	$436M	-6,8x	6,4x
MiNK Therapeutics, Inc.	INKT	Unlock Forecast - 30 Days FREE Trial	$59M	-1,5x	-1,4x
Inmune Bio, Inc.	INMB	Unlock Forecast - 30 Days FREE Trial	$52M	-2,5x	1,8x
INTENSITY THERAPEUTICS, INC.	INTS	Unlock Forecast - 30 Days FREE Trial	$7M	-2,2x	3,4x
IOVANCE BIOTHERAPEUTICS, INC.	IOVA	Unlock Forecast - 30 Days FREE Trial	$851M	-4,5x	1,2x
Century Therapeutics, Inc.	IPSC	Unlock Forecast - 30 Days FREE Trial	$44M	-0,7x	0,2x
iTeos Therapeutics, Inc.	ITOS	Unlock Forecast - 30 Days FREE Trial	$393M	-2,8x	0,7x
Invivyd, Inc.	IVVD	Unlock Forecast - 30 Days FREE Trial	$137M	-0,4x	3,2x
EXOZYMES INC.	IZTC	Unlock Forecast - 30 Days FREE Trial	$99M	x	-27,5x
Jasper Therapeutics, Inc.	JSPR	Unlock Forecast - 30 Days FREE Trial	$44M	-3,2x	1,9x
Jasper Therapeutics, Inc.	JSPRW	Unlock Forecast - 30 Days FREE Trial	$3M	x	0,0x
Kalaris Therapeutics, Inc.	KLRS	Unlock Forecast - 30 Days FREE Trial	$86M	x	1,6x
Klotho Neurosciences, Inc.	KLTO	Unlock Forecast - 30 Days FREE Trial	$26M	x	2,4x
Klotho Neurosciences, Inc.	KLTOW	Unlock Forecast - 30 Days FREE Trial	$1M	x	0,4x
Kodiak Sciences Inc.	KOD	Unlock Forecast - 30 Days FREE Trial	$556M	-2,5x	7,9x
Kiromic Biopharma, Inc.	KRBPQ	Unlock Forecast - 30 Days FREE Trial	$0M	x	x
Krystal Biotech, Inc.	KRYS	Unlock Forecast - 30 Days FREE Trial	$4099M	27,9x	3,9x
Kymera Therapeutics, Inc.	KYMR	Unlock Forecast - 30 Days FREE Trial	$3646M	-17,8x	3,8x
Kyverna Therapeutics, Inc.	KYTX	Unlock Forecast - 30 Days FREE Trial	$170M	x	0,9x
LadRx Corp	LADX	Unlock Forecast - 30 Days FREE Trial	$M	x	x
Lineage Cell Therapeutics, Inc.	LCTX	Unlock Forecast - 30 Days FREE Trial	$271M	-4,7x	5,6x
LENZ Therapeutics, Inc.	LENZ	Unlock Forecast - 30 Days FREE Trial	$1189M	-6,7x	5,8x
Liminatus Pharma, Inc.	LIMN	Unlock Forecast - 30 Days FREE Trial	$0M	x	x
Lexeo Therapeutics, Inc.	LXEO	Unlock Forecast - 30 Days FREE Trial	$271M	-0,4x	2,0x
Maze Therapeutics, Inc.	MAZE	Unlock Forecast - 30 Days FREE Trial	$696M	x	2,7x
MeiraGTx Holdings plc	MGTX	Unlock Forecast - 30 Days FREE Trial	$693M	-3,4x	20,9x
Metagenomi, Inc.	MGX	Unlock Forecast - 30 Days FREE Trial	$72M	x	0,4x
Moderna, Inc.	MRNA	Unlock Forecast - 30 Days FREE Trial	$9457M	-3,2x	1,0x
NEUROCRINE BIOSCIENCES INC	NBIX	Unlock Forecast - 30 Days FREE Trial	$14379M	41,3x	5,3x
NKGen Biotech, Inc.	NKGN	Unlock Forecast - 30 Days FREE Trial	$4M	-0,1x	-0,2x
NKGen Biotech, Inc.	NKGNW	Unlock Forecast - 30 Days FREE Trial	$1M	x	0,0x
Neumora Therapeutics, Inc.	NMRA	Unlock Forecast - 30 Days FREE Trial	$271M	-3,9x	1,5x
NOVAVAX INC	NVAX	Unlock Forecast - 30 Days FREE Trial	$1411M	3,3x	37,5x
Ocugen, Inc.	OCGN	Unlock Forecast - 30 Days FREE Trial	$298M	-4,3x	18,7x
Omega Therapeutics, Inc.	OMGA	Unlock Forecast - 30 Days FREE Trial	$9M	-0,7x	0,8x
Omega Therapeutics, Inc.	OMGAQ	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
VivoSim Labs, INC.	ONVO	Unlock Forecast - 30 Days FREE Trial	$35M	-0,4x	95,9x
Outlook Therapeutics, Inc.	OTLK	Unlock Forecast - 30 Days FREE Trial	$73M	-0,2x	-2,3x
PALISADE BIO, INC.	PALI	Unlock Forecast - 30 Days FREE Trial	$4M	-0,2x	0,7x
Passage BIO, Inc.	PASG	Unlock Forecast - 30 Days FREE Trial	$23M	-0,6x	0,6x
Vaxcyte, Inc.	PCVX	Unlock Forecast - 30 Days FREE Trial	$4348M	-20,4x	1,4x
BiomX Inc.	PHGE	Unlock Forecast - 30 Days FREE Trial	$14M	1,5x	0,7x
Pluri Inc.	PLUR	Unlock Forecast - 30 Days FREE Trial	$-4M	-1,4x	-9,1x
Protalix BioTherapeutics, Inc.	PLX	Unlock Forecast - 30 Days FREE Trial	$120M	19,1x	2,4x
PharmaCyte Biotech, Inc.	PMCB	Unlock Forecast - 30 Days FREE Trial	$7M	-2,6x	0,2x
Prime Medicine, Inc.	PRME	Unlock Forecast - 30 Days FREE Trial	$500M	-1,5x	8,2x
PROKIDNEY CORP.	PROK	Unlock Forecast - 30 Days FREE Trial	$-80M	x	0,0x
Poseida Therapeutics, Inc.	PSTX	Unlock Forecast - 30 Days FREE Trial	$926M	-9,6x	10,6x
Pelthos Therapeutics Inc.	PTHS	Unlock Forecast - 30 Days FREE Trial	$M	x	x
QIAGEN N.V.	QGEN	Unlock Forecast - 30 Days FREE Trial	$10339M	x	2,9x
Quince Therapeutics, Inc.	QNCX	Unlock Forecast - 30 Days FREE Trial	$86M	-1,7x	7,4x
Replimune Group, Inc.	REPL	Unlock Forecast - 30 Days FREE Trial	$932M	-3,8x	2,2x
REPLIGEN CORP	RGEN	Unlock Forecast - 30 Days FREE Trial	$6531M	8219,1x	3,3x
REGENXBIO Inc.	RGNX	Unlock Forecast - 30 Days FREE Trial	$499M	-1,8x	2,3x
Relay Therapeutics, Inc.	RLAY	Unlock Forecast - 30 Days FREE Trial	$707M	-2,0x	1,1x
Revolution Medicines, Inc.	RVMD	Unlock Forecast - 30 Days FREE Trial	$7134M	-11,1x	3,4x
Revolution Medicines, Inc.	RVMDW	Unlock Forecast - 30 Days FREE Trial	$16M	x	0,0x
RECURSION PHARMACEUTICALS, INC.	RXRX	Unlock Forecast - 30 Days FREE Trial	$2110M	-4,7x	2,3x
SAB Biotherapeutics, Inc.	SABS	Unlock Forecast - 30 Days FREE Trial	$24M	-2,3x	1,1x
SAB Biotherapeutics, Inc.	SABSW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Sana Biotechnology, Inc.	SANA	Unlock Forecast - 30 Days FREE Trial	$693M	-2,1x	5,7x
Scilex Holding Co	SCLX	Unlock Forecast - 30 Days FREE Trial	$62M	-0,4x	-0,3x
Scilex Holding Co	SCLXW	Unlock Forecast - 30 Days FREE Trial	$25M	x	-0,1x
Scinai Immunotherapeutics Ltd.	SCNI	Unlock Forecast - 30 Days FREE Trial	$9674M	-287,8x	1231,2x
SANGAMO THERAPEUTICS, INC	SGMO	Unlock Forecast - 30 Days FREE Trial	$131M	-1,6x	6,7x
Solid Biosciences Inc.	SLDB	Unlock Forecast - 30 Days FREE Trial	$495M	-0,9x	1,7x
Silexion Therapeutics Corp	SLXN	Unlock Forecast - 30 Days FREE Trial	$4M	x	34,5x
Silexion Therapeutics Corp	SLXNW	Unlock Forecast - 30 Days FREE Trial	$866M	x	-189,1x
Senti Biosciences, Inc.	SNTI	Unlock Forecast - 30 Days FREE Trial	$51M	-1,1x	1,3x
Scholar Rock Holding Corp	SRRK	Unlock Forecast - 30 Days FREE Trial	$4069M	-18,5x	13,0x
Surrozen, Inc./DE	SRZN	Unlock Forecast - 30 Days FREE Trial	$105M	-0,5x	2,2x
Surrozen, Inc./DE	SRZNW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
SUTRO BIOPHARMA, INC.	STRO	Unlock Forecast - 30 Days FREE Trial	$90M	-1,0x	-2,5x
SpringWorks Therapeutics, Inc.	SWTX	Unlock Forecast - 30 Days FREE Trial	$3539M	-9,9x	8,5x
Protara Therapeutics, Inc.	TARA	Unlock Forecast - 30 Days FREE Trial	$131M	-2,1x	0,9x
Tarsus Pharmaceuticals, Inc.	TARS	Unlock Forecast - 30 Days FREE Trial	$2216M	-12,4x	6,7x
TC BioPharm (Holdings) plc	TCBP	Unlock Forecast - 30 Days FREE Trial	$37M	x	34,5x
TC BioPharm (Holdings) plc	TCBPW	Unlock Forecast - 30 Days FREE Trial	$1M	x	1,0x
TC BioPharm (Holdings) plc	TCBPY	Unlock Forecast - 30 Days FREE Trial	$13M	x	12,0x
TScan Therapeutics, Inc.	TCRX	Unlock Forecast - 30 Days FREE Trial	$248M	-4,6x	1,4x
BIO-TECHNE Corp	TECH	Unlock Forecast - 30 Days FREE Trial	$8155M	75,2x	4,0x
Tectonic Therapeutic, Inc.	TECX	Unlock Forecast - 30 Days FREE Trial	$314M	-8,9x	1,1x
Instil Bio, Inc.	TIL	Unlock Forecast - 30 Days FREE Trial	$182M	-1,1x	1,3x
Tenaya Therapeutics, Inc.	TNYA	Unlock Forecast - 30 Days FREE Trial	$184M	-2,5x	1,9x
Tourmaline Bio, Inc.	TRML	Unlock Forecast - 30 Days FREE Trial	$688M	-3,5x	2,7x
Turnstone Biologics Corp.	TSBX	Unlock Forecast - 30 Days FREE Trial	$8M	-0,1x	0,6x
Taysha Gene Therapies, Inc.	TSHA	Unlock Forecast - 30 Days FREE Trial	$919M	-3,0x	3,7x
TITAN PHARMACEUTICALS INC	TTNP	Unlock Forecast - 30 Days FREE Trial	$8M	-0,5x	4,5x
Tevogen Bio Holdings Inc.	TVGN	Unlock Forecast - 30 Days FREE Trial	$168M	x	-29,3x
Tevogen Bio Holdings Inc.	TVGNW	Unlock Forecast - 30 Days FREE Trial	$11M	x	-1,9x
Twist Bioscience Corp	TWST	Unlock Forecast - 30 Days FREE Trial	$1549M	-12,6x	3,2x
Voyager Acquisition Corp./Cayman Islands	VACH	Unlock Forecast - 30 Days FREE Trial	$-1436M	x	0,0x
Voyager Acquisition Corp./Cayman Islands	VACHU	Unlock Forecast - 30 Days FREE Trial	$-1585M	x	0,0x
Vericel Corp	VCEL	Unlock Forecast - 30 Days FREE Trial	$1703M	239,6x	5,6x
Vigil Neuroscience, Inc.	VIGL	Unlock Forecast - 30 Days FREE Trial	$384M	-1,1x	9,3x
Vir Biotechnology, Inc.	VIR	Unlock Forecast - 30 Days FREE Trial	$732M	-2,0x	0,8x
VivoSim Labs, INC.	VIVS	Unlock Forecast - 30 Days FREE Trial	$3M	x	0,3x
Vor Biopharma Inc.	VOR	Unlock Forecast - 30 Days FREE Trial	$246M	-0,6x	3,9x
Vaxart, Inc.	VXRT	Unlock Forecast - 30 Days FREE Trial	$87M	-0,9x	2,7x
Voyager Therapeutics, Inc.	VYGR	Unlock Forecast - 30 Days FREE Trial	$248M	570,6x	1,0x
WINDTREE THERAPEUTICS INC /DE/	WINT	Unlock Forecast - 30 Days FREE Trial	$18M	-0,4x	4,2x
X4 Pharmaceuticals, Inc	XFOR	Unlock Forecast - 30 Days FREE Trial	$8M	6,4x	0,4x
Zivo Bioscience, Inc.	ZIVO	Unlock Forecast - 30 Days FREE Trial	$57M	-31,3x	-2,0x
Zura Bio Ltd	ZURA	Unlock Forecast - 30 Days FREE Trial	$131M	5,0x	0,9x

Häufig gestellte Fragen - Omega Therapeutics, Inc. Aktienprognose

Wie genau sind die Omega Therapeutics, Inc.-Aktienprognosen?

Our AI model demonstrates 56% historical accuracy for OMGA predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

Welche Faktoren beeinflussen Omega Therapeutics, Inc. Aktienkursprognosen?

Unsere Analyse berücksichtigt die Finanzkennzahlen von Omega Therapeutics, Inc., Life Sciences Branchentrends, die Marktstimmung, technische Indikatoren, Ertragsdaten und makroökonomische Faktoren, die die Aktienperformance beeinflussen.

Ist Omega Therapeutics, Inc. eine gute Investition im Jahr 2025?

Nach unserer KI-Analyse zeigt Omega Therapeutics, Inc. Potenzial für verschiedene Marktszenarien. Berücksichtigen Sie Ihre Risikotoleranz, Ihren Anlagezeitraum und die Diversifizierung Ihres Portfolios, bevor Sie Anlageentscheidungen treffen.

Wie oft werden die Omega Therapeutics, Inc.-Prognosen aktualisiert?

Omega Therapeutics, Inc. Aktienprognosen werden täglich auf der Grundlage von Echtzeit-Marktdaten aktualisiert, um sicherzustellen, dass Sie die aktuellsten KI-gestützten Vorhersagen und Investitionseinblicke erhalten.

Möchten Sie eine erweiterte Omega Therapeutics, Inc.-Analyse?

Schalten Sie Premium-Funktionen wie detaillierte Kursziele, Risikobewertungen, Portfolio-Optimierung und Echtzeit-Warnungen für Omega Therapeutics, Inc. Aktien frei.

🎯 Premium-Analyse erhalten 📊 Mehr Aktien erforschen

Mein Portfolio

Investitions-Dashboard

Laden Sie Ihr Portfolio...

Cookie Preferences

Cookie Settings

Essential Cookies

Analytics Cookies

Herzlich willkommen!

Omega Therapeutics, Inc. (OMGA) AI-Aktienkursprognose & Investitionsanalyse ⛶Vollbild

Omega Therapeutics, Inc. Aktienkurs-Chart und technische Analyse